ctDNA is helping us track what truly matters—real-time, personalized signals that guide smarter decisions in cancer care.
Varied Cancer Perspectives
Explore a comprehensive range of insights and information within our ‘Varied Cancer Perspectives’ category. From melanoma to breast cancer, colorectal cancer to sarcoma, and beyond, this diverse collection delves into the multifaceted world of oncology. Gain a nuanced understanding of different cancer types, treatments, and the latest advancements in research. Whether you’re seeking knowledge on pediatric oncology, uveal melanoma, or desmoid tumors, our curated content provides a holistic view, offering valuable perspectives to empower and inform those navigating the complexities of cancer care. Join us on a journey through varied perspectives, ensuring a well-rounded understanding of the ever-evolving landscape of cancer.
News broke today that President Joe Biden has been diagnosed with stage IV (metastatic) prostate cancer. As an oncologist, this is not just a headline—it becomes an important teaching moment for how we evaluate and manage newly diagnosed metastatic prostate cancer. With the public eye now focused, many are likely wondering: what does this diagnosis …
This post was inspired by a recent review in the New England Journal of Medicine — click here to read it. What moved me most was the extraordinary time, effort, and global collaboration it took to transform the outlook for patients with Ph+ ALL. This progress was only possible because of the clinical trials carried …
Just got back from family spring break vacation and sincerely appreciative of the great feedback I was getting after changing the format of the blog to personal stories from the clinic and every day life as a medical oncologist. I’ll still include updates with FDA approvals or interesting topics from the current news every so …
Prostate cancer is one of the most common cancers in men, yet many people have only a basic understanding of what it is, how it’s diagnosed, and the different treatment options available. Whether you or a loved one has recently been diagnosed, or you’re looking for a clear, comprehensive overview, this guide will walk you …
For years, the treatment of esophageal carcinoma has been a subject of debate, with varying multimodal approaches tailored based on tumor location and staging. Traditionally, gastric cancer patients often underwent perioperative FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) followed by surgical resection. Meanwhile, esophageal carcinoma patients were typically treated with neoadjuvant chemoradiotherapy (CROSS regimen: carboplatin/paclitaxel with radiation) followed by surgery or upfront chemotherapy …
On December 20, 2024, the FDA granted accelerated approval for a groundbreaking new treatment approach for patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation. The newly approved regimen combines encorafenib (Braftovi) with cetuximab and mFOLFOX6 (a chemotherapy regimen consisting of fluorouracil, leucovorin, and oxaliplatin). This marks a pivotal step forward in the …
Multiple myeloma, a complex and challenging hematologic malignancy, has seen remarkable advances in its treatment landscape. Standard care for transplant-eligible patients often involves quad therapy, blending immunomodulatory agents, proteasome inhibitors, anti-CD38 monoclonal antibodies, and corticosteroids. For frail or comorbid patients, triple therapy remains the mainstay. Hospitalized patients frequently benefit from CyBORD (cyclophosphamide, bortezomib, dexamethasone), and …
Stage IV melanoma used to be synonymous with a terminal diagnosis. For years, oncologists faced the grim reality of limited options and poor survival rates for their patients. However, the landscape has changed dramatically over the past decade. Breakthroughs in immunotherapy and clinical research have rewritten the narrative, offering hope to patients and their families. …
The management of chronic lymphocytic leukemia (CLL), one of the most common types of leukemia, has advanced significantly over the past decade. New targeted therapies have reshaped treatment paradigms, providing effective, less toxic options compared to traditional chemoimmunotherapy. At the 2024 ASH Annual Meeting, data from the phase 3 AMPLIFY trial introduced another potential breakthrough …